Cover Image
市場調查報告書

中國的Bevacizumab市場分析

Investigation Report on China Bevacizumab Market ,2010-2019

出版商 China Research and Intelligence 商品編碼 296861
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Bevacizumab市場分析 Investigation Report on China Bevacizumab Market ,2010-2019
出版日期: 2015年07月24日 內容資訊: 英文 20 Pages
簡介

Bevacizumab,自進入中國市場之後,顯示急速成長。年度銷售額,2013年達2億6,500萬人民幣,2010年∼2014年以126.67%的年複合成長率成長。

本報告提供中國的Bevacizumab市場相關調查分析、市場規模、市場佔有率、零售價格、主要製造商、市場預測等相關的系統性資訊。

第1章 Bevacizumab的相關概念

  • 適應
  • 全球市場銷售情形

第2章 中國的Bevacizumab的市場簡介

  • 專利情形與核准資訊
  • 主要製造商
  • 市場規模

第3章 中國的Bevacizumab銷售情形分析

  • 銷售額
  • 銷售額數量

第4章 中國的Bevacizumab主要廠商的市場佔有率分析

  • 市場佔有率:各銷售額
  • 市場佔有率:各銷售數量

第5章 中國的Bevacizumab的各劑型分析

  • 市場佔有率 (各劑型) :各銷售額
  • 市場佔有率 (各劑型) :各銷售數量

第6章 中國的Bevacizumab的醫院標準價格

第7章 中國的Bevacizumab市場主要製造商

第8章 中國的Bevacizumab的市場預測

  • 市場規模的預測
  • 競爭情形的預測

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1507277

Colon cancer is a common gastrointestinal tumor whose incidence varies greatly in different countries. In developed countries, colon cancer is only second to lung cancer among malignant cancers. Its incidence decreases every year in the US and the EU but increases remarkably during the past four decades in Japan. According to the statistics published by the Ministry of Health of the People's Republic of China in 2011, 92-170 out of 1 million people suffer from colon cancer, sex ratio for which is 1.2:1. Although the incidence of colon cancer in China is higher than that in developed countries, it has decreased slightly in recent years.

Developed by Roche under the trade name of Avastin, bevacizumab injection is the first angiogenesis inhibitor in the world. In Feb.26, 2010, it was approved by CFDA to treat metastatic colorectal cancer. Currently, bevacizumab injections available in China all come from Roche and its subsidiary Genectech. In Jul. 2013, Kanion Pharmaceutical's Establishment of Evaluation System of Traditional Chinese Medicine's Efficacy in Treating Gastrointestinal Inflammatory Disease as well as Jiangsu Hengrui Medicine Co., Ltd's Introduction of Monoclonal Antibody Technology and Development of Bevacizumab have been designated by the Ministry of Science and Technology of the People's Republic of China as Key International S&T Cooperation Projects. In Dec. 2013, phase I clinical trial of the generic drug of bevacizumab co-developed by Huahai Pharmaceutical and Oncobiologics was approved to be conducted in the EU.

Bevacizumab injection develops fast after entering China, sales value reaching CNY 265 million in 2013 despite a slight decline in 2014 and CAGR during the period of 2010-2014 reaching 126.67%. With improvements in living standards and lifestyle changes, obesity rate in China goes up gradually, which increases the risk of colorectal cancer. Hence the vast demand for bevacizumab injection in China. Currently, the market is monopolized by Shanghai Roche Pharmaceutical Co., Ltd that brought in a sales value of CNY 264 million in 2014. As some local enterprises are trying to make generic drugs of bevacizumab injection, the monopoly of Roche is expected to be broken by local products in the next few years.

Readers can get at least the following information from this report:

  • market size of bevacizumab in China
  • competitive landscape of bevacizumab in Chinese market
  • price of bevacizumab made by different enterprises in China
  • market outlook of bevacizumab in China

The author suggests the following groups of people purchase this report:

  • manufacturers of monoclonal antibody
  • manufacturers of anti-tumor drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Bevacizumab

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Bevacizumab in China

  • 2.1. Patent Status and Approval Information of Bevacizumab in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Bevacizumab in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Bevacizumab in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Bevacizumab in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Bevacizumab in Chinese Hospitals in 2014

7. Major Manufacturers of Bevacizumab in Chinese Market, 2010-2014

8. Market Outlook of Bevacizumab in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Bevacizumab in China
  • Chart Sales Status of Bevacizumab in China
  • Chart Sales Value of Bevacizumab in China, 2010-2014
  • Chart Sales Value of Bevacizumab in Some Regions in China, 2010-2014
  • Chart Sales Volume of Bevacizumab in China, 2010-2014
  • Chart Sales Volume of Bevacizumab in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Bevacizumab Made by Shanghai Roche Pharmaceutical Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of Bevacizumab Made by Genentech in China, 2010-2014
  • Chart Sales Volume and Market Share of Bevacizumab Made by Shanghai Roche Pharmaceutical Co., Ltd in China, 2010-2014
  • Chart Sales Volume and Market Share of Bevacizumab Made by Genectech in China, 2010-2014
  • Chart Sales Value and Market Share of Bevacizumab Injection in China, 2010-2014
  • Chart Sales Volume and Market Share of Bevacizumab Injection in China, 2010-2014
  • Chart Price of Bevacizumab Made by Shanghai Roche Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top